These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

582 related items for PubMed ID: 27286976

  • 1. MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system.
    Kim S, Nam SJ, Kwon D, Kim H, Lee E, Kim TM, Heo DS, Park SH, Kim CW, Jeon YK.
    BMC Cancer; 2016 Jun 10; 16():363. PubMed ID: 27286976
    [Abstract] [Full Text] [Related]

  • 2. BCL2 expression is associated with a poor prognosis independent of cellular origin in primary central nervous system diffuse large B-cell lymphoma.
    Makino K, Nakamura H, Shinojima N, Kuroda JI, Yano S, Mikami Y, Mukasa A.
    J Neurooncol; 2018 Oct 10; 140(1):115-121. PubMed ID: 29968039
    [Abstract] [Full Text] [Related]

  • 3. [Survival of patients with primary central nervous system diffuse large B-cell lymphoma: impact of gene aberrations and protein overexpression of bcl-2 and C-MYC, and selection of chemotherapy regimens].
    Yin WJ, Zhu X, Yang HY, Sun WY, Wu MJ.
    Zhonghua Bing Li Xue Za Zhi; 2018 Jan 08; 47(1):32-38. PubMed ID: 29325248
    [Abstract] [Full Text] [Related]

  • 4. Primary central nervous system diffuse large B-cell lymphoma shows an activated B-cell-like phenotype with co-expression of C-MYC, BCL-2, and BCL-6.
    Li X, Huang Y, Bi C, Yuan J, He H, Zhang H, Yu Q, Fu K, Li D.
    Pathol Res Pract; 2017 Jun 08; 213(6):659-665. PubMed ID: 28552541
    [Abstract] [Full Text] [Related]

  • 5. Clinical Significance of BCL2, C-MYC, and BCL6 Genetic Abnormalities, Epstein-Barr Virus Infection, CD5 Protein Expression, Germinal Center B Cell/Non-Germinal Center B-Cell Subtypes, Co-expression of MYC/BCL2 Proteins and Co-expression of MYC/BCL2/BCL6 Proteins in Diffuse Large B-Cell Lymphoma: A Clinical and Pathological Correlation Study of 120 Patients.
    Ting CY, Chang KM, Kuan JW, Sathar J, Chew LP, Wong OJ, Yusuf Y, Wong L, Samsudin AT, Pana MNBM, Lee SK, Gopal NSR, Puri R, Ong TC, Bahari SK, Goh AS, Teoh CS.
    Int J Med Sci; 2019 Jun 08; 16(4):556-566. PubMed ID: 31171907
    [Abstract] [Full Text] [Related]

  • 6. MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified.
    Yan LX, Liu YH, Luo DL, Zhang F, Cheng Y, Luo XL, Xu J, Cheng J, Zhuang HG.
    PLoS One; 2014 Jun 08; 9(8):e104068. PubMed ID: 25090026
    [Abstract] [Full Text] [Related]

  • 7. Impact of Double Expression of C-MYC/BCL2 Protein and Cell of Origin Subtypes on the Outcome among Patients with Diffuse Large B-Cell Lymphoma: a Single Asian Center Experience.
    Teoh CS, Lee SY, Chiang SK, Chew TK, Goh AS.
    Asian Pac J Cancer Prev; 2018 May 26; 19(5):1229-1236. PubMed ID: 29801406
    [Abstract] [Full Text] [Related]

  • 8. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
    Staiger AM, Ziepert M, Horn H, Scott DW, Barth TFE, Bernd HW, Feller AC, Klapper W, Szczepanowski M, Hummel M, Stein H, Lenze D, Hansmann ML, Hartmann S, Möller P, Cogliatti S, Lenz G, Trümper L, Löffler M, Schmitz N, Pfreundschuh M, Rosenwald A, Ott G, German High-Grade Lymphoma Study Group.
    J Clin Oncol; 2017 Aug 01; 35(22):2515-2526. PubMed ID: 28525305
    [Abstract] [Full Text] [Related]

  • 9. Rare cases of primary central nervous system anaplastic variant of diffuse large B-cell lymphoma.
    Xu T, Jia Q, Wang Y, Liu Y, Han D, Li P, Ma J, Fan L, Yan Q, Guo S, Li M, Wang Z.
    Diagn Pathol; 2019 May 20; 14(1):45. PubMed ID: 31109360
    [Abstract] [Full Text] [Related]

  • 10. Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma.
    Horn H, Ziepert M, Wartenberg M, Staiger AM, Barth TF, Bernd HW, Feller AC, Klapper W, Stuhlmann-Laeisz C, Hummel M, Stein H, Lenze D, Hartmann S, Hansmann ML, Möller P, Cogliatti S, Pfreundschuh M, Trümper L, Loeffler M, Glass B, Schmitz N, Ott G, Rosenwald A, DSHNHL16.
    Leukemia; 2015 Jul 20; 29(7):1564-70. PubMed ID: 25687653
    [Abstract] [Full Text] [Related]

  • 11. Immunohistochemical overexpression of BCL-2 protein predicts an inferior survival in patients with primary central nervous system diffuse large B-cell lymphoma.
    Chen Y, Chen H, Chen L, Zheng X, Yang X, Zheng Z, Zheng J, Yang T, Liu T, Yang Y, Hu J.
    Medicine (Baltimore); 2019 Nov 20; 98(45):e17827. PubMed ID: 31702637
    [Abstract] [Full Text] [Related]

  • 12. Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers.
    Pedersen MØ, Gang AO, Brown P, Pedersen M, Knudsen H, Nielsen SL, Poulsen T, Wirenfeldt Klausen T, Høgdall E, Nørgaard P.
    PLoS One; 2017 Nov 20; 12(10):e0186983. PubMed ID: 29088292
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. MYC protein expression is associated with poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system.
    Tapia G, Baptista MJ, Muñoz-Marmol AM, Gaafar A, Puente-Pomposo M, Garcia O, Marginet-Flinch R, Sanz C, Navarro JT, Sancho JM, Ribera JM, Ariza A, Mate JL.
    APMIS; 2015 Jul 20; 123(7):596-603. PubMed ID: 26010683
    [Abstract] [Full Text] [Related]

  • 16. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
    Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A, Go RS, Nielsen O, Gadeberg OV, Mourits-Andersen T, Frederiksen M, Pedersen LM, Møller MB.
    J Clin Oncol; 2012 Oct 01; 30(28):3460-7. PubMed ID: 22665537
    [Abstract] [Full Text] [Related]

  • 17. PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival.
    Four M, Cacheux V, Tempier A, Platero D, Fabbro M, Marin G, Leventoux N, Rigau V, Costes-Martineau V, Szablewski V.
    Hematol Oncol; 2017 Dec 01; 35(4):487-496. PubMed ID: 27966264
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.